Congress moves to ban abortion pill, opens manufacturers to unlimited lawsuits

What it does

This bill would immediately withdraw FDA approval of mifepristone (the abortion pill) for pregnancy termination and create a federal private right of action allowing any woman who uses it to sue the manufacturer for any bodily injury or mental health harm she attributes to the drug, including compensatory damages, punitive damages, and attorney's fees. The bill effectively bans the drug from the U.S. market while exposing manufacturers to unlimited civil liability.

Why we flagged it

The bill's operative mechanism is twofold: (1) retroactive withdrawal of FDA approval for a specific drug, and (2) creation of a novel federal tort with unusually broad causation language ("attributable, in whole or in part") that exposes manufacturers to civil liability for subjective harms. This is not primarily a safety measure—it is a ban paired with a liability regime designed to deter future use and manufacture.

What the text implies

• The liability standard (harm 'attributable, in whole or in part') is unusually permissive and may allow claims based on correlation rather than causation, potentially exposing manufacturers to liability for harms unrelated to the drug's pharmacology.
• By creating a federal private right of action, the bill shifts enforcement of product safety from the FDA (a regulatory body with scientific expertise) to individual litigation, which may be less reliable at distinguishing genuine drug-caused harm from coincidental health events.
• The 90-day effective date for the tort creates a window in which the drug remains legal but manufacturers face imminent liability exposure, potentially accelerating market exit before the formal ban takes effect.
• The bill does not preempt state law remedies, meaning women could potentially bring claims under both federal and state law simultaneously, multiplying liability exposure for manufacturers and creating conflicting standards across jurisdictions.
• Retroactive withdrawal of an already-approved drug sets a precedent for Congress to override FDA approval decisions by statute, potentially destabilizing the regulatory framework for all pharmaceuticals.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

The bill restricts access to a medication currently approved by the FDA and used by hundreds of thousands of women annually, eliminating a legal medical option. It simultaneously creates an unusually broad liability standard (harm "attributable, in whole or in part" to the drug, including subjective mental health claims) that may chill future pharmaceutical development and shifts risk from manufacturers to women by making them the primary enforcers of product safety through litigation rather tha

Who stands to gain

• Litigation firms (class action and individual product liability counsel)
• Alternative abortion providers (surgical clinics, out-of-state providers)

Named in the bill

FDA (Food and Drug Administration), Danco Laboratories (manufacturer of Mifeprex), Mifepristone (drug), Mifeprex (brand name), RU-486 (alternate name), Federal Food, Drug, and Cosmetic Act, Section 505 (FDA approval pathway), U.S. District Courts, State courts

Where it stands

11 cosponsors: 11 Republicans.

• Mar 12, 2026 — Introduced · Congress.gov: “Introduced in House”
• Mar 12, 2026 — Referred to House Committee on the Judiciary and House Committee on Energy and Commerce · Congress.gov: “Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a…”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.